Dewpoint Therapeutics Collaborates with Evotec to Accelerate its Oncology Pipeline
Shots:
- As per the collaboration, Dewpoint will leverage Evotec’s fully integrated clinical-enabling INDiGO platform to de-risk & accelerate pre-clinical development candidates to first-in-human clinical studies
- The strategic R&D collaboration will advance Dewpoint’s oncology pipeline programs of condensate modifying therapeutics into IND using Evotec’s integrated data-driven platform INDiGO
- Moreover, the collaboration also allows Dewpoint to maximize capital efficiency while reducing risk as the agreement is based on risk-sharing arrangements. Evotech will be eligible to receive milestone & royalty payments based on the success of overall programs
Ref: Globenewswire | Image: Dewpoint Therapeutics
Related News:- Dewpoint Therapeutics Collaborated with Novo Nordisk to Identify Small Molecule Drugs for Insulin Resistance and Diabetes Progression
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
